The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Abstract
PURPOSE: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations. RESULTS: The panel considered peer-reviewed reports published in English. RECOMMENDATIONS: The diagnosis of metastatic ccRCC should be made using tissue biopsy of the primary tumor or a metastatic site with the inclusion of markers and/or stains to support the diagnosis. The International Metastatic RCC Database Consortium risk criteria should be used to inform treatment. Cytoreductive nephrectomy may be offered to select patients with kidney-in-place and favorable- or intermediate-risk disease. For those who have already had a nephrectomy, an initial period of active surveillance may be offered if they are asymptomatic with a low burden of disease. Patients with favorable-risk disease who need systemic therapy may be offered an immune checkpoint inhibitor (ICI) in combination with a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI); patients with intermediate or poor risk should be offered a doublet regimen (no recommendation was provided between ICIs or an ICI in combination with a VEGFR TKI). For select patients, monotherapy with either an ICI or a VEGFR TKI may be offered on the basis of comorbidities. Interleukin-2 remains an option, although selection criteria could not be identified. Recommendations are also provided for second- and subsequent-line therapy as well as the treatment of bone metastases, brain metastases, or the presence of sarcomatoid features. Participation in clinical trials is highly encouraged for patients with metastatic ccRCC. Additional information is available at www.asco.org/genitourinary-cancer-guidelines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026982 · Cited by 1,791
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, R., Alekseev, B., Rha, S.-Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., Kopyltsov, E., Méndez-Vidal, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035716 · Cited by 1,766
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bensalah, K., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.011 · Cited by 1,456
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,263
Heng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 994
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 946
Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Self-citationSchnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
FLANIGAN, R. C., MICKISCH, G., SYLVESTER, R., TANGEN, C., VAN POPPEL, H., & CRAWFORD, E. D. (2004) · Journal of Urology · doi:10.1097/01.ju.0000110610.61545.ae · Cited by 872
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Vogelbaum, M. A., Brown, P. D., Messersmith, H., Brastianos, P. K., Burri, S., Cahill, D., Dunn, I. F., Gaspar, L. E., Gatson, N. T. N., Gondi, V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02314 · Cited by 832
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Powles, T., Plimack, E. R., Soulières, D., Waddell, T., Stus, V., Gafanov, R., Nosov, D., Pouliot, F., Melichar, B., Vynnychenko, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30436-8 · Cited by 751
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 1×
“belzutifan, recently earned FDA approval for the medical control of primary von Hippel-Lindau syndrome–associated renal cell carcinomas.(131) This agent is actively being assessed in the metastatic setting.”
BackgroundSelf-citationPotters, L., Kavanagh, B., Galvin, J. M., Hevezi, J. M., Janjan, N. A., Larson, D. A., Mehta, M. P., Ryu, S., Steinberg, M., Timmerman, R., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.042 · Cited by 664
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I. H., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 571
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Bex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., van Velthoven, R., del Pilar Laguna, M., Wood, L., van Melick, H. H. E., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5543 · Cited by 492
Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.010 · Cited by 455
Motzer, R. J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O., Tomczak, P., Lyulko, O., Alyasova, A., Harza, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4940 · Cited by 445
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., Senico, P., Niethammer, A., Lu, D. R., Hariharan, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3961 · Cited by 404
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., Picus, J., Small, E. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.012 · Cited by 398
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 382
Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline
Finelli, A., Ismaila, N., Bro, B., Durack, J., Eggener, S., Evans, A., Gill, I., Graham, D., Huang, W., Jewett, M. A. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9645 · Cited by 367
Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., et al. (2020) · Cancer · doi:10.1002/cncr.33033 · Cited by 325
Brożek, J. L., Akl, E. A., Compalati, E., Kreis, J., Terracciano, L., Fiocchi, A., Ueffing, E., Andrews, J., Alonso-Coello, P., Meerpohl, J. J., et al. (2011) · Allergy · doi:10.1111/j.1398-9995.2010.02530.x · Cited by 297
Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F., & Wilt, T. J. (2011) · BJU International · doi:10.1111/j.1464-410x.2011.10629.x · Cited by 266
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Rini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., Verzoni, E., Needle, M. N., & McDermott, D. F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30735-1 · Cited by 261
Trpkov, K., Hes, O., Williamson, S. R., Adeniran, A. J., Agaimy, A., Alaghehbandan, R., Amin, M. B., Argani, P., Chen, Y.-B., Cheng, L., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00779-w · Cited by 258
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Rini, B. I., Dorff, T. B., Elson, P., Rodriguez, C. S., Shepard, D., Wood, L., Humbert, J., Pyle, L., Wong, Y.-N., Finke, J. H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30196-6 · Cited by 257
Escudier, B., Sharma, P., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.02.010 · Cited by 256
Cella, D., Grünwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., Grimm, M.-O., Rini, B. I., Doan, J., Ivanescu, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30778-2 · Cited by 249
Tannir, N. M., Signoretti, S., Choueiri, T. K., McDermott, D. F., Motzer, R. J., Flaifel, A., Pignon, J.-C., Ficial, M., Frontera, O. A., George, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2063 · Cited by 249
Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Kroeger, N., Xie, W., Lee, J., Bjarnason, G. A., Knox, J. J., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishamayan, U. N., Rha, S., et al. (2013) · Cancer · doi:10.1002/cncr.28151 · Cited by 232
Hanna, N., Sun, M., Meyer, C. P., Nguyen, P. L., Pal, S. K., Chang, S. L., de Velasco, G., Trinh, Q.-D., & Choueiri, T. K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7931 · Cited by 229
(2008) · Cited by 225
Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000891 · Cited by 224
Rini, B. I., Stenzl, A., Zdrojowy, R., Kogan, M., Shkolnik, M., Oudard, S., Weikert, S., Bracarda, S., Crabb, S. J., Bedke, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30408-9 · Cited by 220
Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S., & Escudier, B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5305 · Cited by 212
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Renal Tumors: Diagnostic and Prognostic Biomarkers
Tan, P. H., Cheng, L., Rioux-Leclercq, N., Merino, M. J., Netto, G., Reuter, V. E., Shen, S. S., Grignon, D. J., Montironi, R., Egevad, L., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f12e · Cited by 177
Motzer, R. J., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Alekseev, B. Y., Lee, J.-L., Suarez, C., Stroyakovskiy, D., De Giorgi, U., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5981 · Cited by 173
Tang, C., Msaouel, P., Hara, K., Choi, H., Le, V., Shah, A. Y., Wang, J., Jonasch, E., Choi, S., Nguyen, Q.-N., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00528-3 · Cited by 170
Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Négrier, S., Chevreau, C., Joly, F., Geoffrois, L., Ladoire, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02218 · Cited by 164
McDermott, D. F., Cheng, S., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 160
Zaorsky, N. G., Lehrer, E. J., Kothari, G., Louie, A. V., & Siva, S. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.05.007 · Cited by 160
Self-citationSiva, S., Bressel, M., Wood, S., Shaw, M. G., Loi, S., Sandhu, S. K., Tran, B., Azad, A., Lewin, J. H., Cuff, K. E., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.12.006 · Cited by 153
Self-citationLiu, L., Zhang, W., Qi, X., Li, H., Yu, J., Wei, S., Hao, X., & Ren, X. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2442 · Cited by 150
Powles, T. B., Lackner, M. R., Oudard, S. M., Escudier, B. J., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8808 · Cited by 141
Zaid, H. B., Parker, W. P., Safdar, N. S., Gershman, B., Erwin, P. J., Murad, M. H., Boorjian, S. A., Costello, B. A., Thompson, R. H., & Leibovich, B. C. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.07.079 · Cited by 140
Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach
Siva, S., Kothari, G., Muacevic, A., Louie, A. V., Slotman, B. J., Teh, B. S., & Lo, S. S.-M. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.87 · Cited by 135
Self-citationMcDermott, D. F., Lee, J., Bjarnason, G. A., Larkin, J., Gafanov, R. A., Kochenderfer, M. D., Jensen, N. V., Donskov, F. N., Malik, J., Poprach, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02363 · Cited by 133
Cheung, P., Patel, S., North, S. A., Sahgal, A., Chu, W., Soliman, H., Ahmad, B., Winquist, E., Niazi, T. M., Patenaude, F., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.07.026 · Cited by 130
Jonasch, E. W., Corn, P. G., Pagliaro, L. C., Warneke, C. L., Johnson, M. M., Tamboli, P., Ng, C. S., Aparicio, A. M., Ashe, R. G., Wright, J. J., et al. (2009) · Cancer · doi:10.1002/cncr.24685 · Cited by 128
Singla, N., Hutchinson, R. C., Ghandour, R. A., Freifeld, Y. N., Fang, D., Sagalowsky, A. I., Lotan, Y., Bagrodia, A., Margulis, V., Hammers, H. J., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.02.029 · Cited by 127
Nosov, D., Esteves, B., Lipatov, O. N., Lyulko, A. A., Anischenko, A. A., Chacko, R. T., Doval, D., Strahs, A. L., Slichenmyer, W. J., & Bhargava, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3524 · Cited by 126
Masini, C., Iotti, C., Giorgi, U. D., Bellia, S. R., Buti, S., Salaroli, F., Zampiva, I., Mazzarotto, R., Mucciarini, C., Vitale, M. G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.016 · Cited by 122
Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Hawkins, R. E., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., Vynnychenko, I. O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4500 · Cited by 120
Lipton, A., Colombo-Berra, A., Bukowski, R. M., Rosen, L. S., Zheng, M., & Urbanowitz, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040030 · Cited by 111
Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer · doi:10.1002/cncr.27632 · Cited by 110
Rini, B. I., Plimack, E. R., Stus, V. P., Waddell, T., Gafanov, R. A., Pouliot, F., Nosov, D., Melichar, B., Soulières, D., Borchiellini, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4500 · Cited by 108
Powles, T. B., Wheater, M. J., Din, O. S., Geldart, T., Boleti, E., Stockdale, A. D., Sundar, S., Robinson, A. J., Ahmed, I., Wimalasingham, A. G., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.08.035 · Cited by 107
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 103
Self-citationFlaherty, K. T., Manola, J. B., Pins, M., McDermott, D. F., Atkins, M. B., Dutcher, J. P., George, D. J., Margolin, K. A., & DiPaola, R. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9727 · Cited by 101
Zhang, Y., Schoenhals, J. E., Christie, A. L., Mohamad, O., Wang, C., Bowman, I. A., Singla, N., Hammers, H. J., Courtney, K. D., Bagrodia, A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.023 · Cited by 96
Petrelli, F., Coinu, A., Vavassori, I., Cabiddu, M., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.04.001 · Cited by 92
Voss, M. H., Hussain, A., Vogelzang, N. J., Lee, J. L., Keam, B., Rha, S. Y., Vaishampayan, U. N., Harris, W. B., Richey, S. L., Randall, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx493 · Cited by 86
Hirsch, L., Chanzá, N. M., Farah, S., Xie, W., Flippot, R., Braun, D. A., Rathi, N., Thouvenin, J., Collier, K. A., Seront, E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4544 · Cited by 86
Motzer, R. J., Escudier, B. J., Powles, T. B., Scheffold, C., & Choueiri, T. K. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0061-6 · Cited by 75
Bhanvadia, S. K., Psutka, S. P., Burg, M., de Wit, R., Dhillon, H. M., Gyawali, B., Morgans, A. K., Goldstein, D. A., Smith, A. B., Sun, M., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.02.007 · Cited by 75
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach
Shinder, B. M., Rhee, K., Farrell, D. R., Farber, N. J., Stein, M. N., Jang, T. L., & Singer, E. A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00107 · Cited by 67
Self-citationEmamekhoo, H., Olsen, M. R., Carthon, B. C., Drakaki, A., Percent, I. J., Molina, A. M., Cho, D. C., Bendell, J. C., Gordan, L., Kalebasty, A. R., et al. (2021) · Cancer · doi:10.1002/cncr.34016 · Cited by 63
Self-citationChoueiri, T. K., Larkin, J., Pal, S. K., Motzer, R. J., Rini, B. I., Venugopal, B., Alekseev, B. Y., Miyake, H., Gravis, G., Bilen, M. A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100101 · Cited by 58
Procopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., Chiurì, V. E., Bearz, A., Morelli, F., Ortega, C., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.08.011 · Cited by 56
Keizman, D., Ish‐Shalom, M., Пили, Р., Hammers, H. J., Eisenberger, M. A., Sinibaldi, V. J., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.050 · Cited by 54
Gan, C. L., Stukalin, I., Meyers, D. E., Dudani, S., Grosjean, H. A. I., Dolter, S., Ewanchuk, B. W., Goutam, S., Sander, M. S., Wells, J. C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.004 · Cited by 49
McIntosh, A. G., Umbreit, E. C., Holland, L. C., Gu, C., Tannir, N. M., Matin, S. F., Karam, J. A., Culp, S. H., & Wood, C. G. (2020) · Cancer · doi:10.1002/cncr.32991 · Cited by 44
Larcher, A., Fallara, G., Rosiello, G., Re, C., Baiamonte, G., Agnesi, S., Cignoli, D., Colandrea, G., Basile, G., Briganti, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.014 · Cited by 41
Iacovelli, R., Ciccarese, C., Facchini, G., Milella, M., Urbano, F., Basso, U., Giorgi, U. D., Sabbatini, R., Santini, D., Berardi, R., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00732-y · Cited by 39
Labaki, C., Bakouny, Z., Schmidt, A. L., Lipsitz, S. R., Rebbeck, T. R., Trinh, Q., & Choueiri, T. K. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.019 · Cited by 38
Powles, T. B., Brown, J. E., Larkin, J., Jones, R. J., Ralph, C., Hawkins, R. E., Chowdhury, S., Boleti, E., Bhal, A., Fife, K. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw014 · Cited by 32
Cirkel, G. A., Hamberg, P., Sleijfer, S., Loosveld, O. J. L., Dercksen, M. W., Los, M., Polée, M. B., van den Berkmortel, F. W. P. J., Aarts, M. J. B., Beerepoot, L. V., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5202 · Cited by 28
Voss, M. H., Bhatt, R. S., Vogelzang, N. J., Fishman, M., Alter, R. S., Rini, B. I., Beck, J. T., Joshi, M., Hauke, R. J., Atkins, M. B., et al. (2019) · Cancer · doi:10.1002/cncr.32061 · Cited by 26
Self-citationKushnir, I., Basappa, N. S., Ghosh, S., Lalani, A. A., Hansen, A. R., Wood, L. A., Kollmannsberger, C., Heng, D. Y. C., Bjarnason, G. A., Soulières, D., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.05.004 · Cited by 24
Tchelebi, L. T., Batchelder, E., Wang, M., Lehrer, E. J., Drabick, J. J., Sharma, N. K., Machtay, M. X., Trifiletti, D. M., & Zaorsky, N. G. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab050 · Cited by 22
Self-citationTabakin, A. L., Stein, M. N., Anderson, C. B., Drake, C. G., & Singer, E. A. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2343 · Cited by 18
Self-citationNext Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era
Schmidt, A. L., Tabakin, A. L., Singer, E. A., Choueiri, T. K., & McKay, R. R. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320785 · Cited by 18
Self-citationJavier-DesLoges, J. F., Yuan, J. H., Soliman, S. I., Hakimi, K. N., Meagher, M. F., Ghali, F., Hsiang, W. R., Patel, D. N., Kim, S. P., Murphy, J. D., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.16267 · Cited by 10
Chan, A., Dang, C., Wisniewski, J., Weng, X., Hynson, E., Zhong, L., & Wilson, L. (2022) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000884 · Cited by 10
Haaland, B. A., Chopra, A., Acharyya, S., Fay, A. P., & Lopes, G. D. L., Jr. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-592 · Cited by 9
Li, X., Xu, Z., Xu, T., Qi, F., & Song, N. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s340284 · Cited by 8
Geynisman, D. M., Du, E. X., Yang, X., Sendhil, S. R., Tejo, V. D., Betts, K. A., & Huo, S. (2021) · Future Oncology · doi:10.2217/fon-2021-1109 · Cited by 4
Cited by
Exosomal microRNA-1 and MYO15A as a target for therapy and diagnosis in renal cell carcinoma
Yoshino, H., Tatarano, S., Tamai, M., Tsuruda, M., Iizasa, S., Arima, J., Kawakami, I., Fukumoto, W., Kawahara, I., Li, G., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.056 · Cited by 24
Metadata
- Authors
- Rathmell, W. K., Rumble, R. B., Van Veldhuizen, P. J., Al-Ahmadie, H., Emamekhoo, H., Hauke, R. J., Louie, A. V., Milowsky, M. I., Molina, A. M., Rose, T. L., Siva, S., Zaorsky, N. G., Zhang, T., Qamar, R., Kungel, T. M., Lewis, B., & Singer, E. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-09-01
- Volume
- 40
- Issue
- 25
- Pages
- 2957-2995
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4283220315
- Cited by
- 336
- References
- 120
- FWCI
- 38.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.